<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03030170</url>
  </required_header>
  <id_info>
    <org_study_id>35RC15_9846</org_study_id>
    <nct_id>NCT03030170</nct_id>
  </id_info>
  <brief_title>REinforcement of the Pancreas in distaL pAncreatectomY (REPLAY)</brief_title>
  <acronym>REPLAY</acronym>
  <official_title>Does the Strengthening of the Pancreas in Distal Pancreatectomy Using Endo GIA Reload Reinforced Reduce the Occurrence of Pancreatic Fistula? Multicenter Randomized Prospective Open Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite an improvement regarding morbidity and mortality since 30 years, especially in expert
      centers, pancreatic surgery remains currently associated to a significant postoperative
      morbidity reaching more than 60%. Regarding distal pancreatectomy (DP), the main complication
      following surgery is the occurrence of postoperative pancreatic fistula (PF) which may be
      able to lead an increased risk of bleeding, gastroparesis and finally a longer hospital
      stays. The main risk factors associated to the occurrence of pancreatic fistula are
      represented by the texture of the pancreatic parenchyma (soft pancreas) and the caliber of
      the main pancreatic duct (&lt;3mm). Looking for new means of reducing the occurrence of
      pancreatic fistula is a priority in pancreatic surgery and a genuine public health issue.
      Currently, no formal recommendations concerning the optimal technical for closure of the
      distal stump in DP are available. In fact, manual closing by elective suturing or stapling of
      the main pancreatic duct give similar results. The use of a reinforcing stapling potentially
      represents a simple way to decrease the occurrence of pancreatic fistula and requires
      evaluation by a prospective randomized study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of postoperative pancreatic fistula defined by the criteria of the ISGPF</measure>
    <time_frame>up to 90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gravity of the pancreatic fistula according to the 3 stages of ISGPF</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the occurrence of gastroparesis and its severity according to the criteria of ISGPS</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the occurrence of postoperative haemorrhage</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative mortality and 90-day mortality</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall morbidity classified and categorized according to the classification of Dindo and Clavien</measure>
    <time_frame>until 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization rates</measure>
    <time_frame>until 90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Distal Pancreatectomy (DP)</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stapling of the pancreas with ENDO GIA Reinforced reload</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stapling of the pancreas with ENDO GIA X-tra Thick reload</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ENDO GIA X-tra Thick reload with Tri Staple Technology</intervention_name>
    <description>Suture of the pancreas by normal stapling</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ENDO GIA Articulating Reinforced Reload with Tri-Staple Technology</intervention_name>
    <description>Suture of the pancreas by reinforced stapling</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients who undergo DP whether made by open or laparoscopic surgery

          -  Patients 18 years of age or older,

          -  Benefiting from a social security scheme,

          -  Having given his free, informed and written consent.

        Exclusion Criteria:

          -  History of pancreatic abdominal surgery

          -  Severe co-morbidity type renal failure requiring hemodialysis, unbalanced diabetes,
             major respiratory insufficiency, heart failure ≥ stage 3 NYHA;

          -  Persons of full age who are subject to legal protection, persons deprived of liberty.

          -  Pregnant or nursing women

          -  Patients participating in or participating in another study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LAURENT SULPICE, MD/PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RENNES PONTCHAILLOU HOSPITAL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LAURENT SULPICE, MD/PHD</last_name>
    <email>laurent.sulpice@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>AUDE MERDRIGNAC, MD</last_name>
    <email>aude.merdrignac@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de chirurgie Hépato-pancréato-biliaire</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Safi DOKMAK, MD</last_name>
      <phone>+33 40 87 59 48</phone>
      <email>safi.dokmak@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de chirurgie générale, digestive et de la transplantation hépatique</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Yves MABRUT, MD/PHD</last_name>
      <phone>+33 4 72 07 11 00</phone>
      <email>jean-yves.mabrut@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HM - Institut Paoli Calmettes_ service de chirurgie oncologique digestive</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Turrini Olivier, MD</last_name>
      <phone>+33 4 91 22 33 33</phone>
      <email>turrinio@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de chirurgie digestive et endocrienne</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>REGENET Nicolas, MD</last_name>
      <phone>+33 2 40 08 30 22</phone>
      <email>nicolas.regenet@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Rennes Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unité d'hospitalisation Chirurgie hépatique, biliaire et pancréatique</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sa Cunha Antonio, MD/PHD</last_name>
      <phone>+33 1 45 59 32 07</phone>
      <email>antonio.sacunha@pbr.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2017</study_first_submitted>
  <study_first_submitted_qc>January 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2017</study_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

